Project Management. Dissemination and Exploitation Services in Horizon 2020

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Project Management. Dissemination and Exploitation Services in Horizon 2020"

Transcription

1 Project Management Dissemination and Exploitation Services in Horizon 2020

2 Ontwerp: Studio Edwin de Boer 2

3 Project Management Dissemination and Exploitation Services in Horizon 2020

4 ttopstart - Project Management Our services ttopstart is a European science and business consulting company that specialises in leveraging the impact of your European project through providing professional management, dissemination and exploitation services. ttopstart focuses on projects in the field of life sciences, healthcare and medical technology. Professional Horizon 2020 Project Management Successful consortia have a sound scientific and non-scientific management framework. ttopstart provides professional non-scientific project management services as a full partner of your Horizon 2020 consortium. This allows you to focus on scientific management while ttopstart ensures that your project runs according to plan and fully in line with the EC grant agreement. We like to dedicate our time to the scientific activities within our Horizon 2020 project. General project management activities provided by ttopstart are therefore ideal for the performance of our Horizon 2020 consortium Dissemination and Exploitation services Horizon 2020 promises more breakthroughs and discoveries by taking great ideas from the lab to the market. Broad visibility and (preparing) strong implementation of your project's outcomes are therefore key requirements. ttopstart specialises in developing creative and detailed stakeholdertargeted plans for dissemination and exploitation of the proposed outcomes. Our experience with commercialisation translates directly into highly effective outreach to all relevant stakeholders. Our business strategy experience ensures that we can design a streamlined, lean route to market. The support of ttopstart in our Horizon 2020 project has enabled the start of a new venture to commercialise research tools and diagnostics 4

5 Project Management in Horizon 2020 ttopstart offers full non-scientific project management support as a partner of your Horizon 2020 consortium. Our goal is to facilitate a productive working atmosphere. Professional project management ttopstart has the unique skills and expertise to facilitate the productivity of your Horizon 2020 consortium. We remove the administrative burden associated with (international) projects, allowing you to focus on the work plan. We offer an extended package of project management services, including: Setting up the project management administration; Developing a cloud-based environment to share all project-related documents; Support with managing the budget; Coordination of annual project progress updates; Coordination of the activities for producing the deliverables, such as reports to the EC. Organising consortium meetings; Liaison with the EC; Monitoring the risk management plan. Our project management services are highly complementary to the activities of your consortium and can be customised in close collaboration with the professionals in your own organisation. 5

6 ttopstart - Project Management Project Management - application phase Our services are implemented through a dedicated Consortium Management Work Package, which will be part of your proposal. ttopstart offers the possibility to contribute to the design of this Work Package in the Application Phase. This ensures that your Horizon 2020 project gets an excellent score for the Implementation criterion. This will be based on the best practices we have gained in writing more than 100 EU projects. At project start, we will set up a virtual Project Management Office (PMO) specified to the needs of the project and consortium. Project Management project phase After the project has been granted, ttopstart will (co-)coordinate the Project Management Work Package and will fulfil the task of the PMO. The PMO will set up the material and guidelines to kickstart the project. During the project, the PMO will function as a helpdesk for the project partners. Questions regarding the non-scientific management of the project can be answered by the PMO. 6

7 Management Structure Steering committee PC, PM and vice-chair Representatives of participating institutions Project Management Office Management Team PC and PM WP Leaders Advisory Boards WP 1 WP 2 WP 3 WP 4 WP 5 Figure 1: An example of the position of the PMO co-coordinated by ttopstart 7

8 ttopstart - Project Management Dissemination and Exploitation ttopstart offers effective dissemination and exploitation activities to maximise the impact of your Horizon 2020 project. This will contribute to the overall success of the project, its visibility to relevant stakeholders and its promise to society. Dissemination Dissemination activities Dissemination activities should be carefully designed and well-timed, in order to maximise the visibility of your Horizon 2020 project to all relevant stakeholders. For example, a drug development consortium should disseminate the results to a range of stakeholders including the scientific community, the biotech/pharma industry, patients and society. This has a number of advantages, such as tapping into the enthusiasm and needs of patients, preparing market acceptance and paving the way for commercialisation. Each project has its own unique dissemination strategy. ttopstart can support you with developing a powerful dissemination strategy and will coordinate execution of the plan. How does it work? Application phase (optional) In the application phase, ttopstart can support you with the development of a dedicated Work Package on Dissemination and Exploitation in which the proposed activities are described. The communication and dissemination plan will consist of a detailed description of which communication and dissemination activities will be carried out, as well as how and when. The plan will be specified for each partner and per target audience, including for example (1) healthcare providers, (2) laboratory staff, (3) the scientific community, (4) bio-pharma industry, (5) public health agencies, (6) national governments, (7) patients and (8) the general public. For each stakeholder, the communication objectives, interaction and communication channels, and planning and execution will be worked out in a separate section. In particular, we will work out: Why do we want to communicate with particular stakeholders? What do we wish to communicate? What do we wish to learn from our stakeholders? When should we communicate? What are the best mechanisms for effective communication? What are challenges to effective communication? 8

9 Stakeholders Impact Strategy to maximise impact Patients Patients will benefit from a fast and accurate diagnosis. Inform patient organisations on increase in time and quality of diagnosis. Clinicians Clinicians will work with a preselected patient group which reduces workload and saves costs. Inform through high-impact publications and through KOLs of clinical added value. Diagnostic Laboratories The test can be commercialised by diagnostic laboratories in the near future. Inform through personal meetings. Health insurance companies Pharma, biotech, CROs Scientific community Health insurance companies will benefit from the diagnostic test since it saves healthcare costs. Early stratification will enable the selection of a highly suitable group of patients for a clinical trial. The diagnostic delivers novel knowledge on biomarkers and ther clinical utility. A cost-effectiveness study will be conducted to provide reliable evidence based for decision making. A dedicated industry day will be organised to explore potential partnerships. Through high-impact publications and presentations at conferences. Figure 2: Basic example of dissemination strategy and plans to reach stakeholders from a diagnostic project. Horizon 2020 project phase After the project has been granted, ttopstart will start to carry out the activities described in the dissemination plan. Different generic communication and dissemination tools will be developed including a project website, newsletters, a unique animation (see example here watch?v=tq980gevp0yz) of the project and social media channels. Furthermore, more targeted communication and dissemination tools will be developed and/or organised. These are designed to target a specific audience with a clear message. To take the example of drug development, an industry-day or dedicated workshop can be organised with companies and/or venture capitalists active in this field. The dissemination plans, tools and activities will be set up and managed by ttopstart as a partner (or as subcontractor for specific activities) within your Horizon 2020 project. These activities will fully comply with H2020 guidelines and EC regulations and will incorporate best practices from ongoing EU projects. 9

10 ttopstart - Project Management Exploitation ttopstart is experienced in science and business consulting. We make sure that market players become aware of project outcomes and interested in commercialisation. We have co-founded more than 20 biotech and medtech companies and were instrumental in initiating license agreements with industry, all resulting from EU-funded projects. Exploitation plans The impact of Horizon 2020 is more important than ever. Through broad experience in business development for the biotech/pharma and medtech industries, ttopstart has the network and skills to develop strong exploitation plans and ensure commercialisation of valuable project deliverables. Exploitation plans include a technology transfer strategy, an intellectual property policy, a market analysis and a detailed business plan. ttopstart also supports with a developing clear plans for non-commercial utilisation of valuable deliverables. We develop utilisation plans which can be targeted to different stakeholders such recommendations for policy makers or pave the way towards incorporation of the innovation into treatment guidelines. Market analysis and Business Case For deliverables that are valuable to society or industry, a thorough market analysis will be performed and a business case will be set up to assess the commercial potential. The market analysis will provide the foundation for defining the business strategy. It will consist of several optional components such as: (A) a top-down landscape analysis, including identification of business opportunities, competitive developments and IP potential, (B) a bottom-up market assessment where we identify potential customers and unmet stakeholder needs and (C) a customer examination for determining the interest for buying IP or products. These studies will show if there is a solid business case for commercialisation, including route-tomarket and knowledge protection strategy. This will pave the way for the next step in the commercialisation process: the development of a business plan. 10

11 1. Biomarker discovery 2. Marker validation 3. Assay development Data collection in EU wide Proof of concept SNP analysis Validated gene set genes Kit format High sens/spec 4. Clinical validation studies Retrospective and prospective clinical studies 5. Launch GMP manufacturing Update CE-IVD mark Post-market validation studies 6. Post-market activities Figure 3: Example of diagnostic development plan in a H2020 business plan Business plan development in Horizon 2020 projects If the business case is positive, a comprehensive business plan will be formulated. It will include a presentation of the product and concept, business and IP strategy, business model, partners, market size and dynamics, technical and operational planning, a SWOT analysis, and financial forecasts. The business plan will allow you to commercialise and finance your findings. ttopstart offers support for commercialisation. In the past, this has led to the launch and growth of 7 companies in different EU countries such as DualTpharma ( as a result from the FP7-METOXIA project ( 11

12 ttopstart - Project Management Market research Business strategy Financial planning Define oppertunity Identify unmet needs Identify key success criteria Competitive landscaping IP Landscaping Consult key opinion leaders Map Industrial needs Find strategic partners Etcetera Business model Route to market IP strategy Regulatory strategy Priduct development Corporate mission and vision Strategic partners Unique selling poits Action Plan Investment need Funding plan Revenue model Revenue planning Cash-flow prognosis Balance prognosis Profit & loss prognosis Risk & contingency plan Exit planning Market report Business plan Financial plan Figure 4: Business plan development process Follow-up funding after your Horizon 2020 project Successful Horizon 2020 projects generate innovative project deliverables. The large majority of these deliverables need further investigation and/or validation. The exploitation and utilisation plans form a good start for acquiring follow-up funding within Horizon 2020, including Marie Curie, ERC and Research and Innovation projects. If your Horizon 2020 project results in a new company, there are several different subsidies for Small Medium Enterprises (SMEs) that might propel the process, including Eurostars and the SME Instrument. 12

13 Why ttopstart? Our driver is the contribution to development of innovations that can strongly advance healthcare, such as diagnostics and treatments for a wide range of diseases. ttopstart combines science and business professionals in life sciences, medical technology and healthcare ttopstart has been built on the unique combination of science and business with a focus on the sectors life sciences, medical technology and healthcare. Our consultants have a solid scientific background combined with an extensive business skill set. This is a key advantage for your Horizon 2020 application considering the increased EC demands for translation of research, public private partnerships and societal impact. ttopstart consultants are involved in the set up and management of large European projects and have gained the necessary skills and best practices to support these large projects. ttopstart has ample business development expertise ttopstart consultants work for academic institutes, companies, governments, scientific societies, and patient organisations. We have gained the expertise and skill set to communicate with a broad range of different stakeholders. The dissemination and exploitation services are also highly synergised with our business development activities, which is essential for successful exploitation. ttopstart supports over 50 biotech and medtech spin-offs with business plan development, market studies and fund raising for innovative projects. We have developed business plans with unique biotech companies and large academic and medical institutes and European consortia that have resulted in financing rounds, licenses with industrial partners and more than 20 new start-up companies in the field different EU countries. ttopstart has gained experience in many EU projects ttopstart has acquired over 150 million funding for clients over the last 3 years. The experience includes numerous subsidies in life sciences and medical technology such as FP7/Horizon2020, European Research Council, Eurostars, NIH, Erasmus Mundus and IMI. ttopstart collaborates with dozens of universities, academic hospitals and companies in more than 10 European countries. 13

14 ttopstart - Project Management Contact us Jochem Bossenbroek MSc. - partner Patrick de Boer MSc. - partner Marije aan den Toorn, PhD - consultant ir Jasper Levink - partner For more information please contact one of our consultants or visit our website at 14

15 15

16

Business development and strategic planning services. for life sciences and medtech ventures

Business development and strategic planning services. for life sciences and medtech ventures Business development and strategic planning services for life sciences and medtech ventures ttopstart - Business development and strategic planning services Design: Studio Edwin de Boer Business development

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

PROJECT MANAGEMENT SERVICES

PROJECT MANAGEMENT SERVICES PROJECT MANAGEMENT SERVICES Cover image Tumour invasion courtesy of Bettina Weigelin and Peter Friedl, Radboud Universiteit Nijmegen, NL IMPRINT EIBIR Office Neutorgasse 9/2a 1010 Vienna, Austria P: +43

More information

Fast track to Innovation: a new instrument in Horizon 2020

Fast track to Innovation: a new instrument in Horizon 2020 Fast track to Innovation: a new instrument in Horizon 2020 29.01.2015 Webinar Ines Haberl Austrian Research Promotion Agency 29.01.2015 Webinar Fast track to Innovation in Horizon 2020 Content 1. Concept

More information

RFA-OD-14-005: NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01) Kurt Marek, PhD

RFA-OD-14-005: NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01) Kurt Marek, PhD RFA-OD-14-005: NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01) Kurt Marek, PhD Questions Please enter your questions into the webinar chat console If we do not address your question

More information

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system

More information

How to write proposal section 2: IMPACT? The Hague Ines Haberl Austrian Research Promotion Agency

How to write proposal section 2: IMPACT? The Hague Ines Haberl Austrian Research Promotion Agency How to write proposal section 2:? 26.06.2014 Ines Haberl Austrian Research Promotion Agency Content 1. What to consider for section 2.1 and 2.2? 2. Exercise 2 Impact analysis in FP7 3 Evaluation criteria

More information

Nanomedicine in Horizon 2020

Nanomedicine in Horizon 2020 Nanomedicine in Horizon 2020 Heico FRIMA Programme Officer European Commission Directorate-General for Research & Directorate D: Key Enabling Technologies heico.frima@ec.europa.eu ETPN Annual Event 2014

More information

SME support under HORIZON 2020

SME support under HORIZON 2020 Jean-David MALO Head of Unit C-03 Financial Engineering DG Research and SME support under HORIZON 2020 Slides courtesily provided by Unit "Small and Medium-Sized Entreprises" DG Research and Research and

More information

Score grid for SBO projects with a primary economic finality version Januari 2016 1

Score grid for SBO projects with a primary economic finality version Januari 2016 1 Score grid for SBO projects with a primary ecomic finality version Januari 2016 1 SBO E projects score grid - Scientific dimension (S) Scientific dimension S S.1.1 scientific added value relative to the

More information

www.scottish-enterprise.com Andrew Ingram Innovation and Enterprise Services R&D grants/smart: SCOTLAND

www.scottish-enterprise.com Andrew Ingram Innovation and Enterprise Services R&D grants/smart: SCOTLAND Andrew Ingram Innovation and Enterprise Services R&D grants/smart: SCOTLAND R&D Grant Single company or collaborative projects Companies of all sizes (and research orgs in collaborative projects only)

More information

Guide to Public and Private Funding

Guide to Public and Private Funding Guide to Public and Private Funding Introduction to public and private funding Key Public Funding Opportunities Key Private Funding Opportunities Which funding opportunity is right for my business? Do

More information

IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope

IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope IPROVE IN BRIEF What is IPROVE? Whydo we need IPROVE? IPROVE in actions (How?) Partnership (Who?) WHAT An EU project (FP7) financed by the

More information

OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY

OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY NINESIGMA WHITE PAPER OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY How six leading healthcare companies are leveraging Open Innovation to achieve their innovation goals By: Stephen Clulow, Director

More information

EURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases

EURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases EURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases EURORDIS - the European Organisation for Rare Diseases represents 310 rare disease organisations from 34

More information

SME support under Horizon 2020 how to make it work

SME support under Horizon 2020 how to make it work SME support under Horizon 2020 how to make it work Olivier Brunet Unit Regional dimension of innovation Directorate General Research &Innovation European Commission The Multiannual Financial Framework

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the

More information

The European Innovation Council A New Framework for EU Innovation Policy

The European Innovation Council A New Framework for EU Innovation Policy The European Innovation Council A New Framework for EU Innovation Policy EARTO recommendations to the European Commission to initiate further discussion 9 October 2015 Introduction: EIC as a Key Action

More information

Title. Enterprise Europe Network & Innovate UK

Title. Enterprise Europe Network & Innovate UK Enterprise Europe Network & Innovate UK Title Practical help for small and medium businesses engaged with research & innovation. Sub-title Roger Hetherington 9 th December 2014 PLACE PARTNER S LOGO HERE

More information

2016 Call for Projects on ALS Research

2016 Call for Projects on ALS Research 2016 Call for Projects on ALS Research 2016 AriSLA Call for Research Projects: PROMOTING RESEARCH EXCELLENCE IN THE FIGHT AGAINST ALS Deadline: at 1.00 pm, March 17 th 2016 1. Aims of the 2016 AriSLA Call

More information

Connected Health (Priority Area D)

Connected Health (Priority Area D) PRIORITY AREA D: CONNECTED HEALTH ACTION PLAN Connected Health (Priority Area D) Context Connected health and independent living technologies are technologies that facilitate remote delivery of healthcare

More information

Impact & Innovation in H2020 IP Management & Exploitation

Impact & Innovation in H2020 IP Management & Exploitation Impact & Innovation in H2020 IP Management & Exploitation Jörg Scherer Tallinn 04 March 2015 Get your ticket to innovation. Author: expert Dr. Eugene Sweeney 36 years experience of commercialising IP/research

More information

Clinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission

Clinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission Clinical trials: The EU perspective Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission Content 1.EU: The global picture 2.EU & Clinial trials: The

More information

Research proposal (Part B)

Research proposal (Part B) Research and Innovation Actions (RIA) Innovation Actions (IA) Research proposal (Part B) Version 1.1 3 November 2014 Disclaimer This document is aimed at informing potential applicants for Horizon 2020

More information

Big Data for Patients (BD4P) Program Overview

Big Data for Patients (BD4P) Program Overview Big Data for Patients (BD4P) Program Overview [Updated August 5, 2015] Proposal: Big Data for Patients (BD4P) Training Program Page 1 Background The new and emerging field of data science ( Big Data )

More information

STARTUP EUROPE Web Entrepreneurs

STARTUP EUROPE Web Entrepreneurs STARTUP EUROPE Web Entrepreneurs Summary: Active Contracts (ONGOING) TechAllStars Europioneers EurApp App Economy Study Accelerators Assembly Network Crowdfunding Network VCs related to the web DAA2012

More information

The agency perspective: What we do and how we do it

The agency perspective: What we do and how we do it The agency perspective: What we do and how we do it Tim Ryder and Olga Dai 15 July 2011 Who are we? Tim Ryder Scientific Team Leader, Darwin HC MA in Biochemistry; DPhil in Physiology 10 years of experience

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

IP in EU-funded projects

IP in EU-funded projects Welcome to our online training session: IP in EU-funded projects, 04 October 2013 Get your ticket to innovation. Today s speaker Jörg Scherer Managing Director of Research and Project Office (Eurice) GmbH,

More information

HabEat - FP7-245012. HabEat

HabEat - FP7-245012. HabEat HabEat Determining factors and critical periods in food habit formation and breaking in early childhood: a multidisciplinary approach Grant agreement number: FP7-245012 Medium-scale Collaborative Project

More information

(Article 131(2) of the Financial Rules of the Innovative Medicines Initiative Joint Undertaking)

(Article 131(2) of the Financial Rules of the Innovative Medicines Initiative Joint Undertaking) Annual report of the Executive Director to the Discharge on measures taken in the light of the Discharge s recommendations of 2012 in respect of the implementation of the budget of 2010 (Article 131(2)

More information

Spreading Excellence and Widening Participation in Horizon 2020

Spreading Excellence and Widening Participation in Horizon 2020 Spreading Excellence and Widening Participation in Horizon 2020 Widening Infoday - Lisbon 14/03/2014 Telemachos TELEMACHOU, Coordination Widening WP 2014-15 Unit: Spreading Excellence and Widening Participation

More information

The TIPS project is supported by the European Commission through the Seventh Framework Programme for Research and Technological Development /

The TIPS project is supported by the European Commission through the Seventh Framework Programme for Research and Technological Development / FP7 Requirements for your Project's Exploitation Plan Ulrich BOES URSIT Ltd., Bulgaria Outline Goal of the presentation Summarise the exploitation requirements of FP7 Outline Definitions Official documents

More information

BEST PRACTICES RESEARCH

BEST PRACTICES RESEARCH 2013 Frost & Sullivan 1 We Accelerate Growth Entrepreneurial Company of the Year Award Pharmaceutical Knowledge Process Outsourcing North America, 2013 Frost & Sullivan s Global Research Platform Frost

More information

The Medical Communications Agency

The Medical Communications Agency The Medical Communications Agency Paul Hatton E U R O P E U N I T E D S T A T E S A S I A P A C I F I C Objectives What do medical communications agencies do? What might a career in medical communications

More information

1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration?

1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration? ABPI S RESPONSE TO THE BUSINESS, INNOVATION AND SKILLS SELECT COMMITTEE INQUIRY INTO THE STRENGTHS AND WEAKNESSES OF BUSINESS-UNIVERSITY COLLABORATION IN THE UK AND THE UK S PERFORMANCE AGAINST INTERNATIONAL

More information

An Introduction to Valuations

An Introduction to Valuations An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your

More information

Grahame Mansell-Grace Business Development Manager. KEY ISSUES FOR COMMERCIALISING MEDTECH IDEAS 28 November 2013

Grahame Mansell-Grace Business Development Manager. KEY ISSUES FOR COMMERCIALISING MEDTECH IDEAS 28 November 2013 Grahame Mansell-Grace Business Development Manager KEY ISSUES FOR COMMERCIALISING MEDTECH IDEAS 28 November 2013 70 BILLION + * Horizon 2020 is now expected to receive 78.6bn in current prices over the

More information

2015 Initiatives for Proactive Quality Management. Progress through Collaboration

2015 Initiatives for Proactive Quality Management. Progress through Collaboration 2015 Initiatives for Proactive Quality Management Progress through Collaboration 1 2015 AQC Members 2 The Avoca Quality Consortium Accelerating the development of leading practices and industry standards

More information

Spinnovator Public Private Partnership for Spin-offs

Spinnovator Public Private Partnership for Spin-offs A project of Ascenion and Vesalius Biocapital supported by the BMBF 5th International VPM Days Hannover Spinnovator Public Private Partnership for Spin-offs Christian Stein, September 1, 2011 Ascenion

More information

Oportunidades no 7.º Programa-Quadro e no Horizonte 2020 para o setor da Saúde. Sessão de apresentação do ProjetoDo IT

Oportunidades no 7.º Programa-Quadro e no Horizonte 2020 para o setor da Saúde. Sessão de apresentação do ProjetoDo IT Oportunidades no 7.º Programa-Quadro e no Horizonte 2020 para o setor da Saúde Vision Mission Flagship Initiative Innovation Union Europe 2020 (Mar 2010) 6 other Flagships Structural Funds Strategy FP7

More information

STRATEGIC PLAN 2012-2016 Office of Research, Innovation and Economic Development OUR FOUNDATION

STRATEGIC PLAN 2012-2016 Office of Research, Innovation and Economic Development OUR FOUNDATION STRATEGIC PLAN 2012-2016 Office of Research, Innovation and Economic Development OUR FOUNDATION NC STATE MISSION: As a research-extensive land-grant university, North Carolina State University is dedicated

More information

A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field

A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field Introduction The field of regenerative medicine remains at the forefront of personalized medicine and healthcare

More information

Milan, July 22, 2014

Milan, July 22, 2014 Informal Meeting of EU Ministers of Competitiveness (Research) Milan, July 22, 2014 Research Infrastructures: a European Challenge Research infrastructures (RI) play an important role in the advancement

More information

WPI: Project Management and Co-ordination Objectives The purpose of this work package is to manage and co-ordinate the preparatory phase in order to

WPI: Project Management and Co-ordination Objectives The purpose of this work package is to manage and co-ordinate the preparatory phase in order to WPI: Project Management and Co-ordination The purpose of this work package is to manage and co-ordinate the preparatory phase in order to deliver the agreed objectives of this proposal. To manage the preparatory

More information

Impacting through Horizon 2020

Impacting through Horizon 2020 Impacting through Horizon 2020 1 Objectives A analyse, measure and maximise the potential and actual impact of the projects in terms of exploitation capture impact and innovation aspects of the projects

More information

Strengthening the Research Effort means Strengthening the Role of Universities

Strengthening the Research Effort means Strengthening the Role of Universities EUA Response to the EC Communication: Science and technology, the key to Europe s future Guidelines for future European Union policy to support research. I. The policy context 1. The 7 th Framework Programme

More information

Global healthcare solutions

Global healthcare solutions Global healthcare solutions clinical trials pharma/biotech medical technology & supplies Global healthcare solutions for your peace-of-mind A global network with specialist options Global presence with

More information

Cultural and creative industries: policy and COSME Programme

Cultural and creative industries: policy and COSME Programme Cultural and creative industries: policy and COSME Programme Carlo Corazza Head of Unit Tourism, Emerging and Creative Industries DG Internal Market, Industry, Entrepreneurship and SMEs Cultural and creative

More information

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES 24 OCTOBER 2011 INTRODUCTION 1. THE EUROPEAN CONTEXT Centres of expertise (CE) and European Reference

More information

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute

More information

Meeting Priorities of Biotech & Small Pharma Companies

Meeting Priorities of Biotech & Small Pharma Companies Meeting Priorities of Biotech & Small Pharma Companies Dr. Andreas Orfanos, MBBCH,FFPM,MBA Thrasos Therapeutics Inc. Vice President Clinical Research & Development 28 Oct 2015 Montreal Technoparc Private,

More information

Jörg Scherer/Eurice GmbH

Jörg Scherer/Eurice GmbH IP Management in Horizon 2020 Jörg Scherer/Eurice GmbH Paris, 09-12-2014 EU research funding Outcome of FP7 impact assessments Less than 50% of industrial partners use the publicly funded applied research

More information

NMBP calls in 2015. Leadership in Enabling and Industrial Technologies Work Programme 2014-15

NMBP calls in 2015. Leadership in Enabling and Industrial Technologies Work Programme 2014-15 NMBP calls in 2015 Leadership in Enabling and Industrial Technologies Work Programme 2014-15 Nicholas Deliyanakis Deputy Head of Unit Strategy Key Enabling Technologies DG Research and European Commission

More information

IP for SMEs Forum. Roadmap. Experiences of the European IPR Helpdesk Ambassadors: the impact on SMEs

IP for SMEs Forum. Roadmap. Experiences of the European IPR Helpdesk Ambassadors: the impact on SMEs Experiences of the Ambassadors: the impact on SMEs IP for SMEs Forum Paloma Mallorquín EEN madri+d Brussels, 20th November 204 Roadmap EU HD Ambassador cooperation scheme Impact for SMEs in my region STOP

More information

COMMISSION DECISION. of XXX

COMMISSION DECISION. of XXX EUROPEAN COMMISSION Brussels, XXX [ ](2014) XXX draft COMMISSION DECISION of XXX authorising the use of reimbursement on the basis of unit costs for actions requiring the conduct of clinical studies under

More information

NSF INNOVATION CORPS (I-Corps)

NSF INNOVATION CORPS (I-Corps) NSF INNOVATION CORPS (I-Corps) Overview The National Science Foundation (NSF) seeks to develop and nurture a national innovation ecosystem that builds upon fundamental research to guide the output of scientific

More information

IMI Projects : SMEs Contributions and Benefits from Large Public-Private Initiatives on Precompetitive Projects

IMI Projects : SMEs Contributions and Benefits from Large Public-Private Initiatives on Precompetitive Projects IMI Projects : SMEs Contributions and Benefits from Large Public-Private Initiatives on Precompetitive Projects Prof. Hüseyin FIRAT, MD,PhD IMI SAFE-T Applicant Consortium coordinator Partner of the IMI

More information

What is the SynbiCITE 4-Day MBA?

What is the SynbiCITE 4-Day MBA? SynbiCITE 4 day More Business Acumen : Developing Entrepreneurship in Synthetic Biology Building a Synthetic Biology-Rich Biotech Business from Scratch 14-18 December 2015 Imperial College London What

More information

Horizon 2020 - Innovation in der Praxis. Jörg Scherer. European IPR Helpdesk/ Berlin 18/06/2015. Eurice GmbH. European IPR Helpdesk

Horizon 2020 - Innovation in der Praxis. Jörg Scherer. European IPR Helpdesk/ Berlin 18/06/2015. Eurice GmbH. European IPR Helpdesk Horizon 2020 - Innovation in der Praxis Jörg Scherer / Eurice GmbH Berlin 18/06/2015 Speaker profile: Jörg Scherer Managing Director of Research and Project Office (Eurice) GmbH PMO (45 staff members)

More information

STRATEGIC POLICY FORUM ON DIGITAL ENTREPRENEURSHIP. Fuelling Digital Entrepreneurship in Europe. Background paper

STRATEGIC POLICY FORUM ON DIGITAL ENTREPRENEURSHIP. Fuelling Digital Entrepreneurship in Europe. Background paper EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Service Industries Key Enabling Technologies and Digital Economy Introduction STRATEGIC POLICY FORUM ON DIGITAL ENTREPRENEURSHIP Fuelling

More information

Go for the complete package.

Go for the complete package. Go for the complete package. Our services help you stand out in the market. Individual design options while leveraging the benefits of a device platform Flexible prototyping and devices for early studies

More information

Research. Evidence. Our mission: and to improve healthcare delivery. Delivering future health

Research. Evidence. Our mission: and to improve healthcare delivery. Delivering future health Research. Our mission: Evidence. to improve Action. people s HRB Strategy health 2016-2020 and to improve healthcare delivery Delivering future health HRB Strategy 2016-2020 We will lead and support excellent

More information

Making Ontario a Preferred Location for Global Clinical Trials

Making Ontario a Preferred Location for Global Clinical Trials Making Ontario a Preferred Location for Global Clinical Trials Clinical Trials Ontario Inaugural Strategic Plan 2012 2017 Strategic Plan Table of Contents LIST OF ABBREVIATIONS... 3 EXECUTIVE SUMMARY...

More information

1) SCOPE OF THE PROGRAM

1) SCOPE OF THE PROGRAM CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany

More information

Erasmus Mundus Joint Doctorates. Francesco Girotti International Relations Division University of Bologna

Erasmus Mundus Joint Doctorates. Francesco Girotti International Relations Division University of Bologna Erasmus Mundus Joint Doctorates Francesco Girotti International Relations Division University of Bologna Erasmus Mundus Programme Programme funded by the DG Education and Culture First phase: 2004 2008

More information

Horizon 2020 EU s 8th framework programme for research and innovation

Horizon 2020 EU s 8th framework programme for research and innovation Horizon 2020 EU s 8th framework programme for research and innovation Melanie Büscher NCP for SSH NCP for Legal/ Finance Issues E-mail: meb@fi.dk Tlf.: 7231 8729 Your National Contact Point EuroCenter:

More information

Agile Master Data Management TM : Data Governance in Action. A whitepaper by First San Francisco Partners

Agile Master Data Management TM : Data Governance in Action. A whitepaper by First San Francisco Partners Agile Master Data Management TM : Data Governance in Action A whitepaper by First San Francisco Partners First San Francisco Partners Whitepaper Executive Summary What do data management, master data management,

More information

Horizon 2020. Research e-infrastructures Excellence in Science Work Programme 2016-17. Wim Jansen. DG CONNECT European Commission

Horizon 2020. Research e-infrastructures Excellence in Science Work Programme 2016-17. Wim Jansen. DG CONNECT European Commission Horizon 2020 Research e-infrastructures Excellence in Science Work Programme 2016-17 Wim Jansen DG CONNECT European Commission 1 Before we start The material here presented has been compiled with great

More information

BREAKTHROUGH SUPPORT FOR INNOVATIONS AND NEW APPROACHES WITHIN THE MEDICAL TECHNOLOGY AND ASSISTED LIVING SECTORS GLOBAL HEALTH ENTERPRISE

BREAKTHROUGH SUPPORT FOR INNOVATIONS AND NEW APPROACHES WITHIN THE MEDICAL TECHNOLOGY AND ASSISTED LIVING SECTORS GLOBAL HEALTH ENTERPRISE BREAKTHROUGH SUPPORT FOR INNOVATIONS AND NEW APPROACHES WITHIN THE MEDICAL TECHNOLOGY AND ASSISTED LIVING SECTORS Anglia Ruskin GLOBAL HEALTH ENTERPRISE Chelmsford Harlow Southend-on-Sea WE KNOW HOW DIFFICULT

More information

A SME s guide to launching online: Everything small businesses need to know about ecommerce but aren t sure who to ask

A SME s guide to launching online: Everything small businesses need to know about ecommerce but aren t sure who to ask A SME s guide to launching online: Everything small businesses need to know about ecommerce but aren t sure who to ask Welcome to a world where size doesn t matter Launching online can be a daunting prospect

More information

Policy for the Exploitation of University Intellectual property - Formation of New Companies

Policy for the Exploitation of University Intellectual property - Formation of New Companies Policy for the Exploitation of University Intellectual property - Formation of New Companies 1. Introduction By law, the University owns the Intellectual property (IP) generated by its employees in the

More information

Transforming relationships Unleashing innovation

Transforming relationships Unleashing innovation Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries

More information

European IPR Helpdesk

European IPR Helpdesk Services Jörg Scherer CEO Eurice GmbH IP Training Event From Invention to Innovation Oxford, 11-09-2014 STOP EU : Target Groups & General Objectives General Objectives The aims at: raising awareness of

More information

Early Detection Research Network: Validation Infrastructure. Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention

Early Detection Research Network: Validation Infrastructure. Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention Early Detection Research Network: Validation Infrastructure Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention 15 October 2015 Mission The NCI Early Detection Research Network s (EDRN) mission is to implement

More information

Research is everybody s business

Research is everybody s business Research and Development Strategy (DRAFT) 2013-2018 Research is everybody s business 1 Information Reader Box to be inserted for documents six pages and over. (To be inserted in final version, after consultation

More information

European & Developing Countries Clinical Trials Partnership (EDCTP)

European & Developing Countries Clinical Trials Partnership (EDCTP) European & Developing Countries Clinical Trials Partnership (EDCTP) EDCTP funding opportunities Lara Pandya North-North Networking Officer EDCTP 13 June 2015 What is different in EDCTP2? New legal structure:

More information

Medical Devices (Priority Area E) Context

Medical Devices (Priority Area E) Context PRIORITY AREA E: MEDICAL DEVICES ACTION PLAN Medical Devices (Priority Area E) Context The global medical device market was reported as $296 billion in 2010. Growth varies from 3-9 per cent per annum depending

More information

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations

More information

Making the most of academic drug target discoveries

Making the most of academic drug target discoveries Making the most of academic drug target discoveries Richard Reschen, Isis Innovation, University of Oxford The explosion of new technologies and research techniques, and encouragement from funding agencies

More information

Circular 10/14: Initiatives to assist SMEs in Public Procurement

Circular 10/14: Initiatives to assist SMEs in Public Procurement Ref: DPE108/001/2014 16 April 2014 To Heads of Departments 1 Circular 10/14: Initiatives to assist SMEs in Public Procurement A Dhuine Uasail, 1. In the context of the reform of the Public Service and

More information

FET Open: an evaluator s view

FET Open: an evaluator s view FET Open: an evaluator s view Bart Preneel Dept. Electrical Eng. ESAT COSIC 1 The funding landscape fundamental understanding ERC Marie Curie FWO/FNRS DOC FET IWT SBO EU Industrial Leadership Societal

More information

Rutgers Mini-MBA : BioPharma Innovation

Rutgers Mini-MBA : BioPharma Innovation Rutgers Mini-MBA : BioPharma Innovation Ga i n t h e s k i l l s to t r a n s f o r m scientific i n n ovat i o n i n to business success www.cmd.rutgers.edu/innovation Rutgers Mini-MBA : BioPharma Innovation

More information

Impact and Knowledge Exchange Strategy 2013-2016 Delivering Impact from Research Excellence

Impact and Knowledge Exchange Strategy 2013-2016 Delivering Impact from Research Excellence 1. Background Impact and Knowledge Exchange Strategy 2013-2016 Delivering Impact from Research Excellence Impact is the demonstrable contribution that excellent research (basic, user-inspired and applied)

More information

WP 2014-2015 Enhancing Innovation Capacity of SME Brussels, 25 November 2013. Enterprise and Industry

WP 2014-2015 Enhancing Innovation Capacity of SME Brussels, 25 November 2013. Enterprise and Industry WP 2014-2015 Enhancing Innovation Capacity of SME Brussels, 25 November 2013 Enterprise and Industry Activities formerly under CIP/EIP Structure and big themes Horizon2020 Excellent Science [~31.7%] Various

More information

Research Design Service London

Research Design Service London Research Design Service London Enabling Better Research Peter Lovell Programme Manager 27 th October 2011 Overview of presentation An introduction to the NIHR Research Design Service (RDS) Outline of the

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

Fulfil your potential with a career in medical communications

Fulfil your potential with a career in medical communications Fulfil your potential with a career in medical communications What is a medical writer? Medical writers combine their knowledge of science and their research skills to write scientific copy, which is used

More information

Transforming Healthcare Delivery

Transforming Healthcare Delivery Ibn Sina (Bldg 27), #301, Dubai Healthcare City, P.O.Box 8703, Dubai, UAE. Ph + 971 4 454 4631, Fax + 971 4 4546003. E-mail info@eurohealthsystems.com Web www.eurohealth.ae Transforming Healthcare Delivery

More information

Intellectual Property in Horizon 2020 overview with a focus on comparison with FP7

Intellectual Property in Horizon 2020 overview with a focus on comparison with FP7 European IPR Helpdesk Intellectual Property in Horizon 2020 overview with a focus on comparison with FP7 The European IPR Helpdesk is managed by the European Commission s Executive Agency for Small and

More information

Guidelines for applicants for the 1 st Transnational Call for Proposals (pre-proposal phase)

Guidelines for applicants for the 1 st Transnational Call for Proposals (pre-proposal phase) SUSFOOD - An FP7 ERA-NET on Sustainable Food Production and Consumption Guidelines for applicants for the 1 st Transnational Call for Proposals (pre-proposal phase) Closing date for pre-proposals: 03 May

More information

Public funding policies: which options for small innovative companies in 2009. Biotech SMEs in the EU: how to improve access to finance

Public funding policies: which options for small innovative companies in 2009. Biotech SMEs in the EU: how to improve access to finance Public funding policies: which options for small innovative companies in 2009 Biotech SMEs in the EU: how to improve access to finance Dirk Carrez Director, EuropaBio EuroBio - 25 September 2009 (Lille)

More information

ICT in the Health, demographic change and well being challenge

ICT in the Health, demographic change and well being challenge ICT in the Health, demographic change and well being challenge Stephen O Reilly National Delegate & Contact Point for ICT & FET Health Information Day January 16 th 2014 A new approach A new approach.

More information

Certification of Electronic Health Record systems (EHR s)

Certification of Electronic Health Record systems (EHR s) Certification of Electronic Health Record systems (EHR s) The European Inventory of Quality Criteria Georges J.E. DE MOOR, M.D., Ph.D. EUROREC EuroRec The «European Institute for Health Records» A not-for-profit

More information

Industry s view: How to match the services paradigm. by Markus Probeck, EARSC Director

Industry s view: How to match the services paradigm. by Markus Probeck, EARSC Director Industry s view: How to match the services paradigm by Markus Probeck, EARSC Director What is EARSC? EARSC is a trade association (NPO), founded in 1989, which represents European companies: offering and

More information

Horizon 2020. Work Programme 2016-2017. 5. Leadership in enabling and industrial technologies - Introduction

Horizon 2020. Work Programme 2016-2017. 5. Leadership in enabling and industrial technologies - Introduction EN Horizon 2020 Work Programme 2016-2017 5. Important notice on the second Horizon 2020 Work Programme This Work Programme covers 2016 and 2017. The parts of the Work Programme that relate to 2017 are

More information

Clinical Trials Jurisdictional Working Group: Update

Clinical Trials Jurisdictional Working Group: Update ACTA International Clinical Trials Symposium Clinical Trials Jurisdictional Working Group: Update James Cokayne Principal Policy Officer, Research Ethics and Governance Unit NSW Office for Health and Medical

More information

REFLECTIVE 6-2015: Innovation ecosystems of digital cultural assets

REFLECTIVE 6-2015: Innovation ecosystems of digital cultural assets HORIZON 2020 WP 2014 2015 Europe in a changing world inclusive, innovative and reflective Societies Reflective Societies: Cultural Heritage and European Identities REFLECTIVE 6-2015: Innovation ecosystems

More information

Research and Innovation Strategy: delivering a flexible workforce receptive to research and innovation

Research and Innovation Strategy: delivering a flexible workforce receptive to research and innovation Research and Innovation Strategy: delivering a flexible workforce receptive to research and innovation Contents List of Abbreviations 3 Executive Summary 4 Introduction 5 Aims of the Strategy 8 Objectives

More information